| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10912287 | Lung Cancer | 2005 | 7 Pages |
Abstract
Paclitaxel and gemcitabine is an active and well-tolerated combination in advanced NSCLC. Patients on this trial had no significant change in their QOL as assessed by the FACT-L questionnaire.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Heidi H. Gillenwater, Thomas E. Stinchcombe, Bahjat F. Qaqish, Maureen Tyann, Thomas A. Hensing, Mark A. Socinski,